evidence table

Nicotinamide Cognitive Performance Randomized Trial Evidence Table

Name: Nicotinamide Cognitive Performance Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Nicotinamide Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Nicotinamide Cognitive Performance Randomized Trial	The decline of nicotinamide adenine dinucleotide (NAD) with aging may elevate risk of Alzheimer’s disease and related neurocognitive disorders (ADRD) by impairing cellular energy metabolism and reducing cerebral blood flow.	2	Martens Christopher R (2025)	A phase‐II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Nicotinamide Cognitive Performance Randomized Trial	Perfusion of the left hippocampus increased with NR (pre: 51.7 ± 3.3; post: 58.0 ± 3.8 ml/min/100g) compared with placebo (pre: 55.6 ± 2.8; post: 51.7 ± 2.3 ml/min/100g; interaction= 0.033); however, this was not associated with the change in memory performance.	2	Martens Christopher R (2025)	A phase‐II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Nicotinamide Cognitive Performance Randomized Trial	We conducted a 12‐week double‐blind, randomized, placebo‐controlled pilot study to evaluate the safety, tolerability, and preliminary efficacy of the NADprecursor, nicotinamide riboside (NR; 500 mg b.i.d.), for enhancing cognitive function and cerebral perfusion in older adults with mild cognitive impairment (MCI).	2	Martens Christopher R (2025)	A phase‐II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Nicotinamide Cognitive Performance Randomized Trial	This review summarizes current evidence on nutritional compounds that target aging-related pathways, focusing on interventions that influence mitochondrial health, cognitive performance, immune function, metabolic regulation, and maintenance of muscle mass in older adults.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
Nicotinamide Cognitive Performance Randomized Trial	Recent findings Evidence indicates that several targeted nutrients, including protein, probiotics, antioxidants, and emerging mitochondrial-support compounds, may contribute to healthy aging.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
Nicotinamide Cognitive Performance Randomized Trial	A personalized, evidence-informed supplementation strategy integrated with exercise and balanced nutrition may help optimize physiological function in aging adults.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
Nicotinamide Cognitive Performance Randomized Trial	Purpose of review Aging is marked by progressive physiological decline driven by chronic inflammation, mitochondrial dysfunction, and impaired metabolic and musculoskeletal resilience.	4	Kurtz JA (2026)	Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.